Peptide bioregulators are short synthetic peptides, typically 2 to 4 amino acids long, that are proposed to regulate gene expression at the cellular level. They were developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology beginning in the 1970s. The most well-known is epithalon (also spelled epitalon), a tetrapeptide derived from the pineal gland that has been shown to activate telomerase in cell culture studies. Epithalon is the most well-known Khavinson peptide; see our Epithalon: The Telomere Peptide for Anti-Aging in 2026 guide.
Key Takeaway
Khavinson peptide bioregulators are an interesting area of longevity research with over 40 years of published data, mostly from Russian institutions. Epithalon has shown telomerase activation and telomere lengthening in cell studies. Clinical evidence, while intriguing (including a 6-8 year human study showing reduced mortality), comes primarily from a single research group and has not been independently replicated by Western labs. Treat this field as promising but unproven by conventional Western standards. Bioregulators feature in many The Ultimate Longevity Peptide Stack for Maximum Healthspan protocols.
Who Is Vladimir Khavinson and What Did He Discover?
Vladimir Khavinson is a Russian gerontologist who has spent over five decades studying peptide-based approaches to aging. He began his research in the 1970s at the Military Medical Academy in St. Petersburg, where he extracted peptide fractions from animal organs and tested their effects on corresponding human tissues. His core hypothesis was that short peptides could interact directly with DNA and regulate gene expression in tissue-specific ways.[1]
Khavinson developed several peptide preparations from animal organ extracts:
- Epithalamin (later synthesized as epithalon/epitalon): derived from the bovine pineal gland, proposed to regulate the neuroendocrine system and activate telomerase
- Thymalin: derived from the thymus, proposed to regulate cellular immunity
- Cortexin: derived from the cerebral cortex, proposed to regulate brain function
- Prostatilen: derived from the prostate, proposed to regulate prostate function
His research group has published over 800 papers and holds numerous patents. Khavinson is a full member of the Russian Academy of Medical Sciences and has received the Russian State Prize for his work. Several of his preparations (Thymalin, Cortexin, Prostatilen) are registered medications in Russia.
What Are Peptide Bioregulators and How Are They Different from Other Peptides?
Most therapeutic peptides are relatively large molecules, typically 7 to 40 amino acids in length. Peptide bioregulators are unusually short, usually just 2 to 4 amino acids. Khavinson's theory is that these short peptides can enter the cell nucleus and interact directly with specific DNA sequences, modulating the transcription of genes relevant to the tissue they were derived from.[1]
View data table
| Category | Clinical Interest Score | Detail |
|---|---|---|
| BPC-157 | 88 | Tissue repair and gut healing |
| TB-500 | 82 | Injury recovery |
| Sermorelin | 78 | Growth hormone support |
| Ipamorelin | 75 | Anti-aging and recovery |
| GHK-Cu | 70 | Skin and tissue repair |
This is a non-standard model of peptide action. Conventional pharmacology does not widely accept the idea that dipeptides and tripeptides can selectively regulate gene expression by direct DNA interaction. The mechanism is plausible at a basic biophysics level (short peptides can fit in the DNA grooves), but the specificity and selectivity claims are where skepticism arises.
The bioregulator concept holds that each organ produces specific short peptides during normal function, and aging is partly caused by declining production of these peptides. Supplementing with the correct peptide for a given tissue restores gene expression to a younger pattern. This is the theoretical framework, not a proven mechanism.
What Is Epithalon and What Does the Telomerase Data Show?
Epithalon (AEDG, or Ala-Glu-Asp-Gly) is a synthetic tetrapeptide based on epithalamin, the natural extract from the pineal gland. It is the most studied of the Khavinson bioregulators and the one that has generated the most interest in Western longevity circles.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →The primary claim is that epithalon activates telomerase, the enzyme that maintains telomere length. Telomeres are the protective caps on the ends of chromosomes that shorten with each cell division. When they get too short, cells stop dividing (cellular senescence) or die. Telomerase can rebuild these caps.[2]
Key published findings on epithalon include:
- In human fetal fibroblast cultures, epithalon induced telomerase activity and the cells continued dividing past the 44th passage, while control cells stopped at the 34th passage[2]
- A more recent study found dose-dependent telomere extension and up to 12-fold upregulation of hTERT mRNA expression (the gene for the telomerase catalytic subunit) in normal human cells[3]
- In animal studies, long-term treatment with epithalon increased mean lifespan by 20-40% in rodent models[2]
These results are interesting, but context matters. Most of this data comes from Khavinson's own research group. Independent replication by Western labs has been limited, and several reviewers have noted that the proposed mechanisms remain uncertain.
What Did the Human Clinical Studies Show?
The most cited clinical study involved 266 elderly and older persons who were followed for 6 to 8 years. Participants received either Thymalin, Epithalamin, a combination of both, or placebo. The group receiving both peptides showed a statistically significant reduction in mortality rate compared to controls.[2]
This is a remarkable claim. A 6-8 year controlled study showing reduced mortality from a peptide intervention would be front-page news in Western gerontology. The fact that it has not been widely adopted or replicated tells you something about how the broader scientific community views the data. The study was conducted at a single center (Khavinson's institute), the methodology details available in English are limited, and no independent group has attempted to replicate the findings.
A separate clinical assessment of Cortexin (the brain-derived peptide bioregulator) showed improved cognitive function scores in elderly patients with cerebrovascular disease. Again, the data comes primarily from Russian clinical settings.[4]
Why Are Khavinson Peptides Popular in Longevity Circles?
Several factors drive their popularity:
The telomere narrative. Telomere biology is well-established science. The 2009 Nobel Prize in Physiology or Medicine was awarded for research on telomeres and telomerase. Epithalon taps into this legitimate scientific framework, which gives it credibility by association even though the specific evidence for epithalon's effects is much thinner than the general telomere science.
The longevity data. Rodent lifespan extension of 20-40% and a human study showing mortality reduction are exactly the kind of results that longevity enthusiasts are looking for. The fact that these results come from a single research group does not deter people who are already comfortable operating outside mainstream medical consensus.
Low perceived risk. Bioregulators are very short peptides (2-4 amino acids). They are similar in size to dipeptides and tripeptides that you get from normal protein digestion. The reasoning (correct or not) is that substances this small and this similar to natural metabolites are unlikely to cause harm.
Oral availability claims. Unlike most peptides, some bioregulators are claimed to be orally active because of their small size. Several companies sell them as capsules. This makes them more accessible than injectable peptides. peptide therapy guide For peptide basics, see our Peptide Therapy: Complete Guide to Benefits, Types, and Safety [2026].
What Do Western Researchers Think?
The response from Western gerontology has been cautious to skeptical. The main concerns are:
Single-group data. Nearly all published evidence comes from Khavinson's institute or closely affiliated researchers. Independent replication is the gold standard in science, and it has not happened here at a meaningful scale.
Mechanism plausibility. The idea that a dipeptide can selectively regulate gene expression in a tissue-specific manner by direct DNA interaction is not supported by mainstream molecular biology. Short peptides can interact with DNA, but the claim of precise tissue-specific regulation goes beyond what has been demonstrated in independent studies.
Publication standards. Many of the original studies were published in Russian journals and translated or summarized for English-language publications. The level of methodological detail available for peer review is sometimes limited compared to what Western journals require.
Conflict of interest. Khavinson holds patents on many of these peptides and is commercially involved in their distribution. This does not invalidate the research, but it does create a conflict of interest that increases the burden of proof.
None of this means the peptides do not work. It means the evidence has not met the threshold that Western regulatory and academic systems require before they accept a therapeutic claim. The Fountain of Youth Stack: Anti-Aging Peptide Protocols Explained
What Are the Common Bioregulator Peptides and Their Proposed Functions?
| Peptide | Sequence | Source Organ | Proposed Function |
|---|---|---|---|
| Epithalon (AEDG) | Ala-Glu-Asp-Gly | Pineal gland | Telomerase activation, neuroendocrine regulation |
| Thymalin | Complex extract | Thymus | Immune regulation, T-cell function |
| Vilon (KE) | Lys-Glu | Thymus (synthetic) | Immune modulation |
| Cortexin | Complex extract | Cerebral cortex | Neuroprotection, cognitive function |
| Vesugen (KED) | Lys-Glu-Asp | Blood vessels | Vascular health, endothelial function |
| Cardiogen (AEDL) | Ala-Glu-Asp-Leu | Heart muscle | Cardiac tissue regeneration |
Notice that several of these are just 2-3 amino acids long. To put that in perspective, these are shorter than the dipeptides your body generates during normal protein digestion. The question is whether these specific sequences, when administered exogenously, can produce the targeted biological effects that Khavinson claims.
What About Safety and Dosing?
Published safety data for bioregulators is generally positive, with no serious adverse events reported in the clinical studies available in English. The 6-8 year human study with Thymalin and Epithalamin did not report significant side effects.[2]
Typical epithalon protocols involve subcutaneous injection of 5-10 mg daily for 10 to 20 consecutive days, repeated 1-2 times per year. Some practitioners use a protocol of 10 mg daily for 10 days, then take several months off before repeating.
Oral bioregulator capsules are sold by several companies, typically containing 10-20 mg of the peptide per capsule, taken daily for 10-30 days. Whether oral bioregulators survive digestion intact and reach target tissues is debated. Proponents argue their small size protects them from enzymatic breakdown, but this has not been rigorously demonstrated.
Frequently Asked Questions
Is epithalon FDA-approved?
No. Epithalon is not FDA-approved for any indication. It is available as a research peptide. The published data on telomerase activation comes from cell culture and animal studies, with limited human clinical evidence. Any use is considered experimental and off-label.
Can you take bioregulator peptides orally?
Several companies sell oral bioregulator capsules, and proponents argue that their very small size (2-4 amino acids) allows them to survive digestion. This claim has not been verified by independent pharmacokinetic studies. Injectable administration provides more reliable bioavailability for peptides in general.
Does epithalon actually extend telomeres in humans?
Epithalon has been shown to activate telomerase and extend telomeres in human cell cultures. Whether this translates to measurable telomere lengthening in living humans has not been demonstrated in published, peer-reviewed clinical trials. The cell culture data is promising but not the same as proof of clinical efficacy.
Are Khavinson peptides safe?
Published studies report no significant adverse effects. The peptides are very short (2-4 amino acids), which limits their potential for immunogenicity or toxicity. The 6-8 year human study did not report safety concerns. That said, long-term safety data from independent studies is not available.
How is epithalon typically dosed?
The common protocol is 5-10 mg subcutaneous injection daily for 10-20 consecutive days, repeated once or twice per year. Some clinics use a 10-day cycle with 5-6 month gaps between cycles. These protocols are based on clinical practice patterns, not standardized clinical trial dosing.
Why has Western medicine not adopted Khavinson peptides?
The evidence base does not meet Western regulatory standards. The research comes primarily from one group, has not been independently replicated, and the proposed mechanism (direct DNA interaction by dipeptides) is not accepted in mainstream molecular biology. This does not prove the peptides are ineffective, but it means they cannot be marketed as treatments in the US or EU.
Does FormBlends offer epithalon or other bioregulators?
FormBlends specializes in SEMAGLUTIDE and TIRZEPATIDE prescribed through licensed telehealth providers. This article provides educational information about peptide bioregulators. Contact a qualified provider for access to specific peptide therapies.
Medical References
- Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PMID: 19830585
- Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. PMID: 14523363
- Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025. PMC12411320
- Khavinson VK, et al. Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results. Adv Gerontol. 2012;25(4):696-708. PMID: 24003726
- Khavinson VK. Publications and research overview. St. Petersburg Institute of Bioregulation and Gerontology. khavinson.info
This article is for educational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting any peptide protocol. FormBlends connects you with licensed providers who can evaluate your individual health needs.
Reviewed by the FormBlends Medical Team. Last updated: 2026-04-10